Publications by authors named "Bernd Bokemeyer"

Claim this Profile
H
Healthcare resource utilization and cost in pediatric celiac disease: A case-control study using German insurance data.
Sibylle Koletzko, Svitlana Schnaidt, Leonarda Serdani-Neuhaus, Juliane Sünwoldt, Christina Dünweber, Bernd Bokemeyer

J Pediatr Gastroenterol Nutr· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-Year Observation Data Reveal Reduction in Concomitant Steroid Overuse for Inflammatory Bowel Disease in Germany.
Ann-Sophie Stratil, Benjamin Friedrich, Patrizia Brunner, Stefan Rath, Steffeni Papukchieva, Bernd Bokemeyer

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Golimumab in Ulcerative Colitis: A Pooled Analysis from the Prospective UMBRELLA-IBD Registry in Germany.
Arne Bokemeyer, Thomas Wenske, Sandra Plachta-Danielzik, Bernd Bokemeyer

J Clin Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author response to "Comment on: Burden of coeliac disease in Germany: real world insights from a large retrospective health insurance claims database analysis".
Bernd Bokemeyer, Leonarda Serdani-Neuhaus, Juliane Sünwoldt, Christina Dünweber, Svitlana Schnaidt

Therap Adv Gastroenterol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen-driven expansion of public clonal T-cell populations in inflammatory bowel diseases.
Mitchell Pesesky, Ramit Bharanikumar, Lionel Le Bourhis, Hesham ElAbd, Elisa Rosati, Bernd Bokemeyer

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T and B cell responses against Epstein-Barr virus in primary sclerosing cholangitis.
Hesham ElAbd, Mitchell Pesesky, Gabriel Innocenti, Brian K Chung, Aya K H Mahdy, Bernd Bokemeyer

Nat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany.
Wolfgang Kruis, Petra Jessen, Julia Morgenstern, Birgitta Reimers, Nike Müller-Grage, Bernd Bokemeyer

World J Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study.
Bernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, Stefanie Howaldt, Wolfgang Mohl

J Crohns Colitis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment.
Bernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, Romina di Giuseppe, Herbert Deppe

J Crohns Colitis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Evaluation of the Prediction Score for a Mild Course of Crohn's Disease (PreMiCC) in Newly Diagnosed Patients With Crohn's Disease: The PROGNOS Study.
Wolfgang Kruis, Bernd Bokemeyer, Petra Jessen, Mark Hoesl, Michael Mroß

Inflamm Bowel Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire.
Eman Al Sulais, Edouard Louis, Bernd Bokemeyer, Krisztina B Gecse, Gareth C Parkes

J Crohns Colitis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of coeliac disease in Germany: real-world insights from a large retrospective health insurance claims database analysis.
Bernd Bokemeyer, Leonarda Serdani-Neuhaus, Juliane Sünwoldt, Christina Dünweber, Svitlana Schnaidt

Therap Adv Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Women with IBD Show Higher Psychophysiological Burden in Comparison to Men with IBD.
Franziska Schulz, Ann Christina Foldenauer, Lara Weidmann, Anne Kerstin Thomann, Andrea Oliver Tal, Bernd Bokemeyer

J Clin Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignass

Z Gastroenterol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching within out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis.
Evi Zhuleku, Daniel Wirth, Riikka Nissinen, Ivana Bravatà, Despina Ziavra, Bernd Bokemeyer

Therap Adv Gastroenterol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl

Inflamm Bowel Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD study).
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica

Aliment Pharmacol Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease.
Isa Maria Steiner, Bernd Bokemeyer, Tom Stargardt

Eur J Health Econ· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi

Expert Opin Biol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. Authors' reply.
Bernd Bokemeyer, Sandra Plachta-Danielzik

Aliment Pharmacol Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO -study.
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl

Aliment Pharmacol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Ulf Helwig, Niels Teich

Aliment Pharmacol Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany.
Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin, Haridarshan Patel

Int J Colorectal Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study.
Sandra Plachta-Danielzik, Lena Grasskemper, Karen Schmidt, Stefan Schreiber, Bernd Bokemeyer

JMIR Res Protoc· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of disease among patients with prevalent Crohn's disease: results from a large German sickness fund.
Evi Zhuleku, Beatriz Antolin-Fontes, Andras Borsi, Riikka Nissinen, Ivana Bravatà, Bernd Bokemeyer

Int J Colorectal Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis